These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1703588)

  • 41. Mechanisms of arrhythmias and of antiarrythmic activity, with special reference to mexiletine.
    Carmeliet E
    Acta Cardiol Suppl; 1980; (25):5-25. PubMed ID: 6246694
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: I. In vitro study.
    Sosunov EA; Anyukhovsky EP; Rosen MR
    Circulation; 1997 Dec; 96(11):4011-8. PubMed ID: 9403626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction.
    Feld GK; Venkatesh N; Singh BN
    Circulation; 1986 Jul; 74(1):197-204. PubMed ID: 3708774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiarrhythmic effects of combined application of class I antiarrhythmic drugs; addition of low-dose mexiletine-enhanced antiarrhythmic effects of disopyramide and aprindine in various-rate canine ventricular tachycardias.
    Awaji T; Hashimoto K
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):960-6. PubMed ID: 7687723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of action of antiarrhythmic drugs.
    Rosen MR; Hoffman BF
    Circ Res; 1973 Jan; 32(1):1-8. PubMed ID: 4567446
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of Na+ channel blockers on the restitution of refractory period, conduction time, and excitation wavelength in perfused guinea-pig heart.
    Osadchii OE
    PLoS One; 2017; 12(2):e0172683. PubMed ID: 28231318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of hyperkalaemia on the depression of maximum rate of depolarization by class I antiarrhythmic agents in guinea-pig myocardium.
    Wyse KR; Ye V; Campbell TJ
    Br J Pharmacol; 1993 Jan; 108(1):255-61. PubMed ID: 8428209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiarrhythmic activity of quinine in humans.
    Sheldon R; Duff H; Koshman ML
    Circulation; 1995 Nov; 92(10):2944-50. PubMed ID: 7586264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Monk JP; Brogden RN
    Drugs; 1990 Sep; 40(3):374-411. PubMed ID: 2226221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome.
    Satoh Y; Sugiyama A; Tamura K; Hashimoto K
    Jpn J Pharmacol; 2000 Aug; 83(4):327-34. PubMed ID: 11001179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs.
    Chézalviel F; Weissenburger J; Guhennec C; Jagueux M; Davy JM; Vernhet L; Simandoux V; Poirier JM; Cheymol G
    J Cardiovasc Pharmacol; 1993 Feb; 21(2):212-20. PubMed ID: 7679154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog.
    Duker G; Almgren O; Carlsson L
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):458-65. PubMed ID: 1279293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates.
    Roden DM
    Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative cardiac electrophysiologic study of PK 10139, a new antiarrhythmic agent, and quinidine in anesthetized dogs: plasma concentration-response relationships.
    Heckle J; Jaillon P; Jozefczak C; Cheymol G
    J Cardiovasc Pharmacol; 1985; 7(1):18-25. PubMed ID: 2580140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of antiarrhythmic drugs.
    Lüderitz B; Mletzko R; Jung W; Manz M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S48-52. PubMed ID: 1723119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quinidine elicits proarrhythmic changes in ventricular repolarization and refractoriness in guinea-pig.
    Osadchii OE
    Can J Physiol Pharmacol; 2013 Apr; 91(4):306-15. PubMed ID: 23627842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preferential action of mexiletine on central common pathway of reentrant ventricular tachycardia.
    Aizawa Y; Abe A; Ohira K; Furushima H; Chinushi M; Fujita S
    J Am Coll Cardiol; 1996 Dec; 28(7):1759-64. PubMed ID: 8962563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: II. In vivo study.
    Anyukhovsky EP; Sosunov EA; Feinmark SJ; Rosen MR
    Circulation; 1997 Dec; 96(11):4019-26. PubMed ID: 9403627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.